About SAGE Therapeutics (NASDAQ:SAGE)
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380
Debt
Debt-to-Equity RatioN/A
Current Ratio10.11%
Quick Ratio10.11%
Price-To-Earnings
Trailing P/E Ratio-20.52
Forward P/E Ratio-17.51
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$11.58 per share
Price / Book12.56
Profitability
EPS (Most Recent Fiscal Year)($7.09)
Net Income$-270,120,000.00
Net MarginsN/A
Return on Equity-86.14%
Return on Assets-75.79%
Miscellaneous
Employees257
Outstanding Shares45,780,000
SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions
What is SAGE Therapeutics' stock symbol?
SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
How were SAGE Therapeutics' earnings last quarter?
SAGE Therapeutics Inc (NASDAQ:SAGE) released its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.98) by $0.23. During the same period in the previous year, the firm posted ($1.50) EPS. View SAGE Therapeutics' Earnings History.
What price target have analysts set for SAGE?
15 equities research analysts have issued twelve-month price targets for SAGE Therapeutics' stock. Their predictions range from $86.00 to $280.00. On average, they expect SAGE Therapeutics' stock price to reach $185.20 in the next twelve months. View Analyst Ratings for SAGE Therapeutics.
Who are some of SAGE Therapeutics' key competitors?
Some companies that are related to SAGE Therapeutics include Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Merck Group (MKGAF), Genmab As (GNMSF), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ) and BeiGene (BGNE).
Who are SAGE Therapeutics' key executives?
SAGE Therapeutics' management team includes the folowing people:
- Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 65)
- Ms. Kimi E. Iguchi, CFO & Principal Accounting Officer (Age 56)
- Dr. Albert J. Robichaud Ph.D., Chief Scientific Officer (Age 57)
- Ms. Anne Marie Cook Esq., Sr. VP, Gen. Counsel & Sec. (Age 56)
- Dr. Stephen J. Kanes M.D., Ph.D., Chief Medical Officer (Age 53)
Has SAGE Therapeutics been receiving favorable news coverage?
Press coverage about SAGE stock has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.08 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.25 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of SAGE Therapeutics?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SAGE Therapeutics' stock price today?
One share of SAGE stock can currently be purchased for approximately $145.49.
How big of a company is SAGE Therapeutics?
SAGE Therapeutics has a market capitalization of $6.78 billion. The biopharmaceutical company earns $-270,120,000.00 in net income (profit) each year or ($7.09) on an earnings per share basis. SAGE Therapeutics employs 257 workers across the globe.
How can I contact SAGE Therapeutics?
SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]
MarketBeat Community Rating for SAGE Therapeutics (SAGE)
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
SAGE Therapeutics (NASDAQ:SAGE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
15 Wall Street analysts have issued ratings and price targets for SAGE Therapeutics in the last 12 months. Their average twelve-month price target is $185.20, suggesting that the stock has a possible upside of 27.29%. The high price target for SAGE is $280.00 and the low price target for SAGE is $86.00. There are currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.79 | 3.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
2 Strong Buy Rating(s) |
| Consensus Price Target: | $185.20 | $183.9333 | $171.2143 | $86.7857 |
| Price Target Upside: | 27.29% upside | 10.50% upside | 0.12% upside | 37.93% upside |
SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History
SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
SAGE Therapeutics (NASDAQ:SAGE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
SAGE Therapeutics (NASDAQ SAGE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 96.35%
SAGE Therapeutics (NASDAQ SAGE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/18/2018 | Kevin P Starr | Director | Sell | 59,000 | $168.85 | $9,962,150.00 | 326,817 |  |
| 3/6/2018 | Steven M Paul | Director | Sell | 58,139 | $172.00 | $9,999,908.00 | 632,712 | |
| 1/10/2018 | Stephen Kanes | Insider | Sell | 44,000 | $177.18 | $7,795,920.00 | 46,348 | |
| 12/21/2017 | Jeffrey M Jonas | CEO | Sell | 210,247 | $157.45 | $33,103,390.15 | 211,473 | |
| 12/14/2017 | Albert Robichaud | Insider | Sell | 60,000 | $159.43 | $9,565,800.00 | 152,759 | |
| 1/13/2017 | Kimi Iguchi | CFO | Sell | 10,000 | $53.92 | $539,200.00 | | |
| 11/17/2016 | Kimi Iguchi | CFO | Sell | 4,000 | $51.77 | $207,080.00 | 75,739 | |
| 11/11/2016 | Kimi Iguchi | CFO | Sell | 1,500 | $50.59 | $75,885.00 | 79,739 | |
| 9/7/2016 | Kimi Iguchi | CFO | Sell | 2,500 | $40.93 | $102,325.00 | 81,239 | |
| 7/12/2016 | Albert Robichaud | Insider | Sell | 22,000 | $40.00 | $880,000.00 | 140,222 | |
| 7/12/2016 | Kimi Iguchi | CFO | Sell | 5,000 | $49.55 | $247,750.00 | 83,739 | |
| 5/16/2016 | Kevin P Starr | Director | Sell | 850,000 | $31.25 | $26,562,500.00 | 65,227 | |
| 4/19/2016 | Stephen Kanes | Insider | Sell | 21,000 | $38.00 | $798,000.00 | 25,948 | |
| 1/25/2016 | Albert Robichaud | Insider | Sell | 20,000 | $40.02 | $800,400.00 | 162,222 | |
| 9/28/2015 | Stephen Kanes | insider | Sell | 6,000 | $46.42 | $278,520.00 | 46,948 | |
| 9/8/2015 | Kimi Iguchi | CFO | Sell | 3,000 | $54.84 | $164,520.00 | 84,563 | |
| 9/1/2015 | Steven M. Paul | Director | Sell | 20,000 | $52.41 | $1,048,200.00 | 683,650 | |
| 8/31/2015 | Stephen Kanes | Insider | Sell | 12,000 | $53.12 | $637,440.00 | 31,948 | |
| 7/23/2015 | Jeffrey M Jonas | Insider | Sell | 3,000 | $76.79 | $230,370.00 | | |
| 7/6/2015 | Kimi Iguchi | CFO | Sell | 4,000 | $68.00 | $272,000.00 | | |
| 7/1/2015 | Albert Robichaud | Insider | Sell | 16,000 | $72.13 | $1,154,080.00 | | |
| 7/1/2015 | Steven M Paul | Director | Sell | 20,000 | $69.40 | $1,388,000.00 | | |
| 6/24/2015 | Stephen Kanes | Insider | Sell | 6,000 | $74.06 | $444,360.00 | | |
| 6/16/2015 | Jeffrey M Jonas | Insider | Sell | 198,600 | $77.36 | $15,363,696.00 | | |
| 6/8/2015 | Thomas Anderson | Insider | Sell | 5,500 | $79.65 | $438,075.00 | | |
| 6/1/2015 | Albert Robichaud | Insider | Sell | 16,000 | $72.80 | $1,164,800.00 | | |
| 6/1/2015 | Steven M Paul | Director | Sell | 20,000 | $72.34 | $1,446,800.00 | | |
| 2/25/2015 | Stephen Kanes | Insider | Sell | 6,000 | $42.05 | $252,300.00 | | |
| 1/26/2015 | Stephen Kanes | Insider | Sell | 6,000 | $37.29 | $223,740.00 | | |
| 7/23/2014 | James M Frates | Director | Buy | 5,000 | $18.00 | $90,000.00 | | |
| 7/23/2014 | Stephen Kanes | Insider | Buy | 3,000 | $18.00 | $54,000.00 | | |
(Data available from 1/1/2013 forward)
SAGE Therapeutics (NASDAQ SAGE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Sage files U.S. marketing application for PPD med brexanolone; shares up 1% premarket
seekingalpha.com - April 23 at 8:38 AM |
 | Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
finance.yahoo.com - April 23 at 8:38 AM |
| Sage Therapeutics asks FDA to approve lead drug for postpartum depression
finance.yahoo.com - April 23 at 8:38 AM |
| Sage Therapeutics down 7% on Biogen/Ionis deal
seekingalpha.com - April 20 at 4:57 PM |
| Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today
finance.yahoo.com - April 20 at 4:57 PM |
 | Kevin P. Starr Sells 59,000 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - April 19 at 7:18 PM |
| Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
finance.yahoo.com - April 17 at 5:26 PM |
| SAGE Therapeutics (SAGE) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM |
| Brokerages Anticipate SAGE Therapeutics Inc (SAGE) to Post -$1.85 EPS
www.americanbankingnews.com - April 14 at 3:11 PM |
| Sage takeover rumors unfounded
seekingalpha.com - April 10 at 5:03 PM |
 | Noteworthy Tuesday Option Activity: DDS, COST, SAGE
www.nasdaq.com - April 10 at 5:03 PM |
| SAGE Therapeutics (SAGE) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM |
| SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 3:22 AM |
| ValuEngine Upgrades SAGE Therapeutics (SAGE) to "Buy"
www.americanbankingnews.com - April 3 at 12:30 AM |
| SAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.85 Per Share
www.americanbankingnews.com - March 28 at 5:24 PM |
| Sage CEO on post-partum depression, innovation for the co...
finance.yahoo.com - March 28 at 4:55 PM |
| Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’
finance.yahoo.com - March 28 at 4:55 PM |
| Canaccord Genuity Analysts Give SAGE Therapeutics (SAGE) a $210.00 Price Target
www.americanbankingnews.com - March 26 at 8:37 AM |
| SAGE Therapeutics (SAGE) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - March 20 at 9:22 PM |
| Corbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head Contrast
www.americanbankingnews.com - March 18 at 5:20 PM |
 | Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...
www.prnewswire.com - March 16 at 8:58 AM |
 | Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology
www.bizjournals.com - March 16 at 8:58 AM |
| See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
finance.yahoo.com - March 15 at 5:35 PM |
 | Analyst Has 4 Favorite Biotechnology Stocks to Buy Now
www.msn.com - March 15 at 5:35 PM |
| SAGE Therapeutics (SAGE) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - March 11 at 3:52 PM |
| SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 3:54 AM |
| Insider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 58,139 Shares of Stock
www.americanbankingnews.com - March 8 at 6:12 PM |
| Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
finance.yahoo.com - March 6 at 5:17 PM |
| Biotech Jumps After Rival Pushes Back Depression Drug Tests
finance.yahoo.com - March 6 at 5:17 PM |
| 17,200 Shares in SAGE Therapeutics Inc (SAGE) Acquired by Sectoral Asset Management Inc
www.americanbankingnews.com - March 6 at 2:11 PM |
| American International Group Inc. Acquires 2,309 Shares of SAGE Therapeutics Inc (SAGE)
www.americanbankingnews.com - March 6 at 4:22 AM |
| SAGE Therapeutics Inc (SAGE) Stake Lessened by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 2 at 7:50 PM |
| SAGE Therapeutics Inc (SAGE) Shares Bought by State of Wisconsin Investment Board
www.americanbankingnews.com - March 1 at 6:10 PM |
| Analysts Offer Predictions for SAGE Therapeutics Inc's Q1 2018 Earnings (SAGE)
www.americanbankingnews.com - March 1 at 7:14 AM |
| Analysts Issue Forecasts for SAGE Therapeutics Inc's FY2022 Earnings (SAGE)
www.americanbankingnews.com - February 28 at 4:48 PM |
| SAGE Therapeutics (SAGE) PT Raised to $203.00
www.americanbankingnews.com - February 28 at 4:44 PM |
| EAM Investors LLC Invests $3.28 Million in SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - February 28 at 1:56 PM |
| SAGE Therapeutics Inc (SAGE) Position Increased by BlackRock Inc.
www.americanbankingnews.com - February 28 at 5:16 AM |
| SAGE Therapeutics Inc (SAGE) Shares Bought by California Public Employees Retirement System
www.americanbankingnews.com - February 27 at 5:20 AM |
| Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy
finance.yahoo.com - February 26 at 5:22 PM |
| SAGE Therapeutics (SAGE) Research Coverage Started at Morgan Stanley
www.americanbankingnews.com - February 26 at 2:35 PM |
| SAGE Therapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($1.92) Per Share (SAGE)
www.americanbankingnews.com - February 26 at 4:37 AM |
| Analyzing Oncobiologics (ONS) and SAGE Therapeutics (SAGE)
www.americanbankingnews.com - February 25 at 9:24 AM |
| Carillon Tower Advisers Inc. Acquires Shares of 451,097 SAGE Therapeutics Inc (SAGE)
www.americanbankingnews.com - February 25 at 4:58 AM |
 | Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Pipeline Update - Business Wire (press release)
www.businesswire.com - February 24 at 8:44 AM |
| SAGE Therapeutics' (SAGE) Buy Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - February 23 at 5:51 PM |
| Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share
www.americanbankingnews.com - February 22 at 5:20 PM |
| Cellular Dynamics International (ICEL) & SAGE Therapeutics (SAGE) Financial Survey
www.americanbankingnews.com - February 22 at 1:18 PM |
| SAGE Therapeutics (SAGE) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 22 at 12:32 PM |
 | Form 10-K Sage Therapeutics, Inc. For: Dec 31
www.streetinsider.com - February 22 at 8:48 AM |
SAGE Therapeutics (NASDAQ:SAGE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
SAGE Therapeutics (NASDAQ:SAGE) Income Statement, Balance Sheet and Cash Flow Statement
SAGE Therapeutics (NASDAQ SAGE) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
